| 1. |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Eng J Med, 1975, 292(7): 344-347.
|
| 2. |
Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J, 2006, 28(5): 1005-1012.
|
| 3. |
Kishaba T, McGill R, Nei Y, et al. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody. J Med Invest, 2018, 65(3.4): 251-257.
|
| 4. |
Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken), 2016, 68(5): 689-694.
|
| 5. |
Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology, 2014, 53(12): 2196-2203.
|
| 6. |
Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford), 2018, 57(12): 2114-2119.
|
| 7. |
Kato M, Ikeda K, Kageyama T, et al. Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-mda5 antibody-positive dermatomyositis[J/OL]. J Clin Rheumatol. [2019-01-04]. https://journals.lww.com/jclinrheum/Citation/9000/Successful_Treatment_for_Refractory_Interstitial.99084.aspx.
|
| 8. |
Chen ZW, Wang XD, Ye S. Tofacitinib in amyopathic dermatomyositis–associated interstitial lung disease. N Engl J Med, 2019, 381(3): 291-293.
|
